AIDS Treatment News Index, 2004
| Abacavir sensitivity genetics | 399 |
| Abstinence | 402 |
| Access to NIH research | 405 |
| ACT UP "naked truth" demos | 404 |
| Action alerts - good design | 400 |
| ADAP activists needed | 404 |
| ADAP call-in | 401 |
| ADVAX DNA vaccine | 402 |
| AEGIS, abstracts found | 407/408 |
| AEGIS, saving conference abstracts | 406 |
| Africa, cotrimoxazole prophylaxis | 407/408 |
| AIDS Treatment News schedule | 398 |
| AIDSVote | 404 |
| Allen, Chad | 405 |
| Allergy, inexpensive filter | 400 |
| AmfAR | 405 |
| Antibiotic empty pipeline | 404 |
| Antiretroviral pipeline | 398 |
| Antiretroviral treatment guidelines | 406 |
| APOBEC | 403 |
| Atazanavir interaction warning | 407/408 |
| Atherosclerosis risk | 399 |
| Bangkok conference online news | 402 |
| Bangkok conference reports | 404 |
| Bangsberg, Dr. David, interview | 402 |
| Blogs | 400 |
| BMS-488043 | 398 |
| Breakthrough headlines | 407/408 |
| Bush, President George W, Philadelphia | 402 |
| Buyers' clubs | 407/408 |
| Cambodia stops tenofovir trial | 403 |
| CCR5 target | 398 |
| Cialis, Reyataz combination warning | 399 |
| Clinical Care Options | 404 |
| Clinical trials "supersite" | 404 |
| Clinical trials design | 403 |
| Clinton Foundation | 399 |
| Cohen, Dr. Cal, interview part I | 405 |
| Cohen, Dr. Cal, interview part II | 407/408 |
| Conferences, abstracts found | 407/408 |
| Conferences, calendar | 404 |
| Conferences, improving with online | 398 |
| Conferences, missing abstracts | 406 |
| Cotrimoxazole prophylaxis, Africa | 407/408 |
| Crixivan, avoid in pregnancy | 407/408 |
| DAPY antiretrovirals | 407/408 |
| Depression and survival | 403 |
| Depression, Louganis and Allen | 405 |
| Drug interactions, how to check | 400 |
| Drug resistance workshop report | 402 |
| Early HIV diagnosis | 398 |
| Election, U.S. | 406 |
| Election, voter misinformation | 404 |
| Elispot research test questioned | 403 |
| Epzicom combination approved | 403 |
| Erythromycin drug interaction | 405 |
| Filter, inexpensive | 400 |
| Generic drugs, India, patents | 407/408 |
| Global Fund | 399 |
| Global treatment by large deals | 399 |
| Glossaries, AIDS online | 400 |
| Gonorrhea new recommendation | 400 |
| Grants for innovative research | 401 |
| Guidelines, antiretroviral treatment | 406 |
| Hepatitis C major studies | 403 |
| HIV early diagnosis | 398 |
| HIV treatment ideas | 403 |
| Imaging technologies | 398 |
| Immune-based treatment ideas | 403 |
| India, generic drugs, patents | 407/408 |
| Indinavir, avoid in pregnancy | 407/408 |
| Inhaled nitrites | 398 |
| Institute of Medicine | 401 |
| Interactions, drugs, how to check | 400 |
| International AIDS conference, online | 402 |
| Kaiser, Dr. Jon | 398 |
| Kaletra monotherapy | 405 |
| Levitra, Reyataz combination warning | 399 |
| Lipodystrophy, imaging | 398 |
| Louganis, Greg | 405 |
| Marijuana (see medical marijuana) | |
| Mascolini, Mark | 402 |
| Medicaid | 401 |
| Medical marijuana | 402 |
| Medical marijuana | 404 |
| Medicare prescription card | 401 |
| Mental health services and survival | 403 |
| Micronutrients | 398 |
| Monoclonal antibodies | 403 |
| Naked Truth demos | 404 |
| Nevirapine misinformation | 407/408 |
| Nevirapine precautions | 398 |
| New-Fill (see Sculptra) | |
| NIH research access | 405 |
| Nutrition call for information | 404 |
| Once-a-day regimens | 405 |
| Online AIDS glossaries | 400 |
| Online information, conferences | 398 |
| Patents, India | 407/408 |
| Patient assistance, Sculptra | 407/408 |
| Philadelphia trials "supersite" | 404 |
| Pipeline, antiretroviral | 398 |
| Pipeline, new drugs | 404 |
| Poppers | 398 |
| Prescription drug card | 401 |
| Prilosec interaction warning | 407/408 |
| Prison health care | 406 |
| Prison HIV and hepatitis C sites | 398 |
| Protest, Washington DC | 400 |
| Reagan, Ronald | 401 |
| Research grants | 401 |
| Resistance, workshop report | 402 |
| Retroviruses conference 2004 | 398 |
| Retroviruses conference 2005 | 403 |
| Retroviruses conference summaries | 399 |
| Reverset | 398 |
| Reyataz interaction warning | 407/408 |
| Reyataz, Viread combination warning | 399 |
| Schering D | 398 |
| Sculptra hearing update | 399 |
| Sculptra hearing | 398 |
| Sculptra patient assistance info sources | 407/408 |
| Sister Mary Elizabeth, AEGIS | 406 |
| Smarter clinical trials | 403 |
| Spanish AIDS glossaries | 400 |
| Stigma, personal psychology | 402 |
| Subways, Suzy | 400 |
| Subways, Suzy | 407/408 |
| Tenerife resistance workshop | 402 |
| Tenofovir prevention trial | 403 |
| TMC-125 | 400 |
| TMC-125 | 407/408 |
| Treatment fund, Uganda | 402 |
| Treatment guidelines | 406 |
| Treatment interruption | 407/408 |
| Triple-nuke failures training module | 399 |
| Truvada combination approved | 403 |
| Uganda treatment fund | 402 |
| Vaccine trial, U.S. | 402 |
| Viagra, Cialis, Levitra -- Reyataz warning | 399 |
| Vif | 403 |
| Walker, Dr. Bruce | 407/408 |
| White House, first AIDS mention | 401 |
| WHO, cotrimoxazole recommendation | 407/408 |
| Women and Girls, World AIDS Day | 406 |
| Women, depression | 403 |
| World AIDS Day | 406 |
| XV International AIDS conference | 402 |
source: AIDS Treatment News
